Clinical trials: Melphalan
Retinoblastoma
Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma
Conventional treatments of retinoblastoma involves laser photocoagulation, cryotherapy (freezing of the tumor), plaque radiotherapy,external beam radiotherapy, and intravenous chemotherapy.
- Trial name
- Chemosurgery (NCT00901238)
- Testing
- Intra-arterial Chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hematopoietic Stem Cell Transplantation
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
This is an investigator-initiated clinical trial to analysis melphalan pharmacokinetics in pediatric hematopoietic stem cell transplantation patients.
- Trial name
- NCT04937634
- Testing
- Melphalan
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Leukemia, Myelodysplastic Syndromes
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
RATIONALE: Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00641030
- Testing
- clofarabine, melphalan, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
MDS
Reduced Intensity Conditioning for MDS
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potential cure for Myelodysplastic syndrome (MDS). Currently, the conditioning regimen for MDS allogeneic transplantation still follows AML, and there are fewer…
- Trial name
- NCT07085156
- Testing
- Fludarabine; melphalan; busulfan
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Ruijin Hospital
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
This pilot clinical trial studies whole-body radiation therapy, systemic chemotherapy, and high-dose chemotherapy followed by stem cell rescue in treating patients with poor-risk Ewing sarcoma.
- Conditions
- Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT01795430
- Testing
- etoposide, ifosfamide, intensity-modulated radiation therapy
- Where
- United States
- Sponsor
- City of Hope Medical Center
Lymphoma
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00907036
- Testing
- alemtuzumab, donor lymphocytes, cyclosporine
- Volunteers
- 49 people
- Sponsor
- Cancer Research UK
Refractory Acute Myeloid Leukemia
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of Fludarabine + Busulfan +…
- Trial name
- NCT04904237
- Testing
- Aza-Ven-allo-HSCT
- Where
- 3 sites in China
- Volunteers
- 23 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Retinoblastoma
Intra-arterial Chemotherapy for Children With Retinoblastoma
Retinoblastoma is a cancer of the eye that occurs exclusively in children. The treatment for retinoblastoma may include surgery, chemotherapy, radiation and local treatments to the eye such as freezing (cryotherapy) and local…
- Trial name
- NCT00906113
- Testing
- Intra-arterial injection of melphalan, Injection of melphalan into the ophthalmic artery
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach.
- Trial name
- NCT00629798
- Testing
- Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
High-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation (HSCT) is considered standard treatment for patients with multiple myeloma.
- Trial name
- NCT01040026
- Testing
- Treatment with in vitro expanded haploidentical NK cells
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Peritoneal Neoplasms, Neoplasm Metastasis
HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
In this registry study the investigators will collect data about patients' disease, treatment, and response to treatment to include in both our local and national databases.
- Conditions
- Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
- Trial name
- NCT02082886
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Edward-Elmhurst Health System
Hematologic Malignancies, Nonmalignant Diseases
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609827
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004165
- Testing
- filgrastim, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Northwestern University
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Malignant Hematologic Disorders
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the…
- Trial name
- NCT03615144
- Testing
- Melphalan, Thiotepa, Clofarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00800150
- Testing
- fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center